Miragen Therapeutics Inc (MGEN) Annual Balance Sheets

Annual · GAAP · USD millions
Access MGEN quarterly Balance Sheets →
Tracking balance sheet results across Miragen Therapeutics Inc to helps illustrate how Dec 31 2019's financial position has responded to changing business conditions.
Annual Report, GAAP in USD millions
ITEM
(Dec 31 2019)
Assets
Short-term Investments, Total2.00
Cash & Short-term Investments1.00
Accounts receivable0.11
Other Current Assets24.85
Prepaid Expense And Other Assets Current2.79
Total Current Assets29.74
Equipment/Property/Plant Net0.52
Total Assets30.26
Liabilities
Accounts Payable, Current AC1.10
Accrued Liabilities, Current AC5.11
Notes Payable, Current NO3.98
Total Current Liabilities10.18
Long-term debt4.33
Total Long-term Debt4.33
Total Liabilities14.51
Stockholders' Equity
Common Stock Value0.35
Additional Paid In Capital Common Stock183.57
Retained Earnings / Accumulated Deficit-168.20
Other Equity0.03
Common Stockholder's Equity15.75
Total Stockholder's Equity15.75
Liabilities & Stockholder's Equity30.26
4 historic quarters locked

Sign in to unlock the full Miragen Therapeutics Inc balance sheet history.

About Viridian Therapeutics Inc de Annual Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-K filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: February 26, 2026
  • Source: vrdn-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001590750-26-000007

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.

Get the full CSIMarket dataset: Subscribe API License